48 results about "Rna expression" patented technology

It was discovered that by binding to CTCF which is important for maintaining chromosomal structures, hSATII RNA inhibits the function thereof, changes chromosome interaction, and induces transcription of inflammation-associated genes. It has also been discovered that cell death can be selectively induced in senescent cells and cancer cells by suppressing hSATII RNA expression. From the obtained results, it has been found that cancer treatment which targets senescent stromal cells and cancer cells can be performed with a substance that suppresses hSATII RNA or a substance that increases CTCF expression. In addition, cancer can be detected early by measuring the expression and activity of hSATII RNA and CTCF, and an epigenomic change of the hSATII DNA region. Thus, it is possible to provide a therapeutic drug for a cancer associated with cellular senescence, a method for screening thereof, and a test support method.

The present disclosure is directed to a split ribozyme biosensor system. Additionally, a genetically modified plant, plant tissue, or plant cell comprising the split ribozyme biosensor system is described. Methods for examining in vivo RNA expression in plants, plant cells or plant tissues are disclosed. Lastly, disclosed herein is a kit comprising the split ribozyme biosensor system.

Described herein are techniques for predicting whether a subject will respond to an immune checkpoint inhibitor (ICI) therapy based on RNA expression data and cytometry data obtained for the subject. In some embodiments, the techniques include: obtaining the RNA expression data, the RNA expression data having been previously obtained from a tumor sample from the subject; selecting, using the RNA expression data, an MF profile type for the tumor sample; obtaining the cytometry data, the cytometry data having been previously obtained from a blood sample from the subject; determining, using the cytometry data, a G2 score for the blood sample, wherein the G2 score is indicative a likelihood that the blood sample is of a Primed (G2) immunoprofile type of multiple immunoprofile types; and predicting, based on the selected MF profile type and the G2 score, whether the subject will respond to the ICI therapy.

The application belongs to the technical field of biological medicine, and particularly relates to application of long-chain non-coding RNA expression inhibition in esophageal cancer ferroptosis inducer sensitization. The application first reveals dynamic change of long-chain non-coding RNA ENSG00000250658 in esophageal squamous cell carcinoma metastasis based on single-cell sequencing data, detects expression of ENSG00000250658 in esophageal squamous cell carcinoma tissue and correlation with prognosis by using LNA probe-based RNA in-situ hybridization technology, and first finds that knocking down ENSG00000250658 can increase killing effect of ferroptosis inducer on esophageal squamous cell carcinoma cells. Therefore, the application provides a new technical scheme and thought for clinical diagnosis and treatment of esophageal cancer.

The application discloses a kind of for sensitizing lung cancer radiotherapy biomimetic nano delivery system and preparation method and application, it belongs to the field of biological medicine, wherein, biomimetic nano delivery system is core-shell structure, including core and the shell of the core outer layer being wrapped;Wherein, core is the lipid nanoparticle of therapeutic nucleic acid being loaded;Shell is tumor cell membrane vesicle;Therapeutic nucleic acid is the short hairpin RNA expression plasmid of targeted deubiquitinating enzyme CYLD gene.The application solves lung cancer radiotherapy resistance problem from mechanism, by therapeutic nucleic acid specific knockdown deubiquitinating enzyme CYLD gene, effectively blocks CYLD / NRP1 signal shaft, to reverse the metabolic reprogramming of tumor cell, significantly enhance its radiotherapy sensitivity, realize to the low-toxicity treatment of radiation resistance lung cancer.

Aspects of the invention provide an AAV product that delivers an FXN gene supplementation or replacement strategy throughout the human CNS and heart at levels of DNA biodistribution, RNA expression, and FXN protein levels expected to restore function in Friedrich's ataxia patients.

This invention provides drugs and methods for the targeted delivery of payloads to cells. These drugs and methods are useful for delivering therapeutic or diagnostic agents to target cells. [Solution] In one embodiment, the present invention includes the step of administering RNA encoding a peptide or polypeptide (docketing compound) comprising a binding portion that binds to a target cell (primary targeting portion) and a further binding portion (secondary target) that binds to a drug comprising a payload (effector probe). After RNA expression, the primary targeting portion may bind to a target antigen such as a cancer antigen on a cancer cell, and then the secondary targeting portion contained in the effector probe may target the secondary target, thereby accurately delivering the "payload" to the target cell such as a cancer cell.

The invention discloses a sequence optimization method for improving the stability of circular RNA, application and a product, and belongs to the technical field of biotechnology and molecular biology. In order to solve the problem that the existing circular RNA is easy to be specifically degraded by RNAseK and lysosome after entering a cell, synonymous mutation optimization is carried out on an open reading frame of a target gene of the circular RNA by identifying nucleic acid motifs (a first type of nucleic acid motifs and a second type of nucleic acid motifs) identified by two degradation mechanisms. The optimized circular RNA is prepared by means of in-vitro cyclization of an anabaena I-type intron self-splicing mediator, after cells are transfected, the intracellular RNA expression level of the circular RNA is remarkably improved compared with that of a wild type, and the target protein expression efficiency is also remarkably improved. The intracellular stability and expression efficiency of the circular RNA are remarkably enhanced, and the method can be widely applied to the scenes of gene expression regulation, protein synthesis, gene therapy, vaccine development and the like.

Provided herein are methods, compositions, systems, kits and uses for integrated, simultaneous spatial multiomic analyses of tissues and samples including chromatin accessibility epigenomic analysis, RNA expression transcriptomic analysis, cell cluster and cell lineage analysis, transcription factor motif analysis, extrachromosomal DNA analysis and mitochondrial DNA analysis.

The invention belongs to the technical field of biological genes, and discloses a method for identifying RNA interaction protein based on a Turbo ID technology and an MCP / MS2 system, the method can be used for identifying protein interacting with RNA in vitro or in vivo, and the method specifically comprises the following steps: firstly, respectively constructing RNA expression vectors inserted with MS2 tags, then constructing fusion protein vectors expressing MCP-Turbo ID, and finally constructing fusion protein vectors for expressing MCP-Turbo ID; the method comprises the following steps of: inserting RNA (Ribonucleic Acid) into an MS2 tag, transgenosis into a plant receptor by utilizing an agrobacterium tumefaciens mediated genetic transformation method to obtain a transgenic plant material expressing MCP-Turbo ID, combining the RNA inserted with the MS2 tag with the MCP-Turbo ID in vivo / in vitro by utilizing a hybridization or in-vitro incubation method, further enabling the Turbo ID to be adjacent to the RNA, biotinylating the RNA binding protein, and obtaining a transgenic plant material expressing the MCP-Turbo ID. And then enriching biotinylated protein by adopting streptavidin magnetic beads, and identifying and analyzing through Western Blot and mass spectrometry. The method not only solves the problem that the interaction protein of specific RNA in a living cell environment cannot be effectively identified in the prior art, but also can capture a transient or low-affinity RNA-protein interaction relationship.

The invention relates to the technical field of agriculture, in particular to an efficient ABE base editing tool based on Cas12i3 and application of the efficient ABE base editing tool. The Cas12i3-based efficient ABE base editing tool provided by the invention comprises a protein expression cassette and an RNA (Ribonucleic Acid) expression cassette, the protein expression cassette comprises a promoter, a 2 * BP NLS nuclear localization signal fragment, a 2 * adenine deaminase TadA8e, a connecting peptide, a Cas12i3 notch enzyme fragment and a terminator, the RNA expression cassette comprises a promoter, a crRNA sequence and a terminator; wherein the crRNA sequence is composed of a DR sequence and a target specific spacer sequence. The tool realizes efficient and specific single base substitution of A-to-G in a rice genome by utilizing the targeted binding characteristic of Cas12i3 and the efficient deamination activity of 2 * TadA8e, has the advantages of high editing efficiency, low off-target rate, wide application range and the like, provides an efficient and accurate technical means for plant functional genome research and molecular breeding, and has a wide application prospect. The creation of excellent rice varieties can be accelerated.

The application discloses a cell proportion prediction method and device fusing prior biological knowledge, and the method comprises the following steps: inputting mixed RNA expression data of a to-be-detected tissue sample into a pre-trained double-flow deconvolution model, wherein the double-flow deconvolution model comprises a feature extraction module and a feature fusion prediction module, the feature extraction module comprises two parallel branches: a deep neural network and a knowledge-driven sparse neural network, and the data processing process comprises the following steps: inputting the mixed RNA expression data into the deep neural network to extract a data-driven hidden layer high-dimensional feature vector; inputting the mixed RNA expression data into the knowledge-driven sparse neural network to extract a knowledge feature vector conforming to biological rules by using a pre-constructed knowledge mask; and inputting the hidden layer high-dimensional feature vector and the knowledge feature vector into a full connection layer and a Softmax activation function after splicing in the feature fusion prediction module, so as to obtain a prediction result of the proportion of each type of cell in the to-be-detected tissue sample.

The application provides application of a compound of a general formula I or a pharmaceutically acceptable salt, a hydrate, a solvate, a prodrug, a tautomer, a stereoisomer thereof as a MALT1 inhibitor, the MALT1 tumor inhibitor can inhibit the expression of a MALT1 gene or inactivate the function of a MALT1 protein, the compound of the general formula can play the role of inhibiting the expression of the MALT1 gene or inactivating the function of the MALT1 protein by affecting the expression of a MALT1 protein death domain. The screened small molecule compound can inhibit the RNA expression of a marker in tumor cells and delay tumor progression in a tumor model mouse; in addition, when the small molecule compound is combined with an immune checkpoint inhibitor, the small molecule compound can synergize with the immune checkpoint inhibitor, and the curative effect is significantly enhanced.

Provided herein are vectors with engineered regulatory sequences for expression of non-coding RNAs (ncRNAs). Regulatory sequences of expression vectors include a Pol III promoter and a binding site for a Pol II - associated transcription factor. Also provided are compositions comprising provided vectors and methods of using the same, e.g., for expression of ncRNAs, e.g., for gene editing.

Provided are synthetic constructs for providing an enhancer or variant thereof as a promoter to drive RNA expression, as well as nucleic acids, vectors, and cells encoding or comprising said constructs. Associated methods and pharmaceutical compositions for use in therapy are also provided herein.

Multi-modal approaches to predict tumor immune infiltration are based on integrating gene expression data and imaging features in a neural network-based framework. This framework is configured to estimate percent composition, and thus immune infiltration score, of a patient tumor biopsy sample. Multi-modal approaches may also be used to predict cell composition beyond immune cells via integrated multi-layer neural network frameworks.

The invention belongs to the field of modern molecular biotechnology and plant disease-resistant breeding, and particularly relates to a bivalent RNAi expression vector for resisting rice virus RRSV (rice serrated leaf dwarf virus) and SRBSDV (southern rice black-streaked dwarf virus) as well as a construction method and application of the bivalent RNAi expression vector. According to the method, a hairpin RNA expression construct of targeted virus gene segments (RRSV Pns10 and SRBSDV Pns5) regulated and controlled by a phloem specific promoter RTBV (Ribonucleic Acid Ribonucleic Acid) is introduced into rice, so that efficient and lasting genetic resistance to the two main rice viruses is realized. According to the method, the broad-spectrum resistance of rice to RRSV and SRBSDV is remarkably improved, meanwhile, the common metabolic interference problem of a constitutive RNAi system is avoided, and a safe, efficient and generalizable innovative approach is provided for rice antiviral molecular breeding.

The present invention provides a vitro method for screening or identifying pregnant females at risk of developing gestational diabetes mellitus (GDM), the method comprising the steps of: (a) measuring the nucleic acid expression levels of one or more RNAs in a gingival crevicular fluid (GCF) sample obtained from a pregnant female to be screened, and (b) comparing the RNA expression levels obtained in (a) with the expression levels of the same one or more RNA measured in a control GCF sample and determining that the pregnant female screened in (a) is at risk of having gestational diabetes mellitus if the RNA expression levels measured in (a) are deviated or different compared to the RNA expression levels measured in the control GCF sample.

Provided are systems / kits and methods for the preparation of cDNA from a sample of total RNA, in which excess RNA species such as rRNA and tRNA are depleted from the cDNA products via prevention of reverse transcription through competitive binding of DNA oligonucleotide probes that prevent binding and / or extension of randomer reverse primers. This process allows downstream high-throughput sequencing on a library prepared from the cDNA to efficiently profile RNA expression without significant loss of accuracy due to excess RNA species occupying too many reads. Compared to other approaches for excess RNA depletion, such as those based on RNAse H systems, the systems and methods provided herein neither require additional enzymes beyond reverse transcriptase, nor extra purification before reverse transcription.

The invention discloses a probe for detecting EBV infected tissue, a kit and a detection method, and belongs to the technical field of virus detection, the key point of the technical scheme is that the probe for detecting the EBV infected tissue is an EBER-PNA probe, the sequence number is GCGACACATGTCTGC, the EBER-specific target probe and EBER in cells are hybridized, flow cytometry is combined, and the EBER-PNA probe can be used for detecting the EBV infected tissue. The kit is high in specificity, low in background and high in signal-to-noise ratio, the detection method is simple and accurate, EBER RNA expression and protein of the same cell can be efficiently detected, infected and non-infected EBV cell subsets can be recognized, and typing and function comparison are carried out.

The application relates to the field of health assessment, and particularly discloses a ZNF281-based gastric cancer prognosis value evaluation system, which comprises a ZNF281 expression quantification module, which is used for detecting the protein / RNA expression level of ZNF281 in tumor tissue through immunohistochemistry, real-time fluorescent quantitative PCR or Western blot technology; a stemness feature and signal path analysis module, which is used for acquiring the protein expression or cell positive rate of stemness genes CD44 and SOX9; then evaluating the activation state of an IL6 / JAK / STAT3 path, including Western blot detection of a p-STAT3 / STAT3 ratio, ELISA determination of IL6 and CXCL5 cytokine levels; then analyzing the cancer-associated fibroblast infiltration in a tumor microenvironment, quantifying the CAF density through alpha-SMA immunofluorescence staining, and combining single-cell sequencing analysis of the interaction strength of a CXCL5 / CXCR2 signal shaft. The technical scheme of the application can integrate the expression amount of ZNF281, signal path activity and clinical pathological data, and precisely stratify the chemotherapy sensitivity and prognosis of gastric cancer patients.

In the present invention, the inventors reveal that noncoding RNA, a known source of noncanonical peptides (also called dark matter) and tumour-specific antigens, can shape the precancer immune contexture and are associated with polyp and cancer risk. Through the multimodal characterisation of a unique dataset of 135 well-annotated cancer and precancer lesions from patients developing polyps at low and high frequency, the inventors identified high expression of noncoding RNAs, as a major differentiator of polyp development rate. Noncoding RNAs were also associated with increased immunogenicity associated with increased mature tertiary lymphoid structures within the microenvironment of pre-cancer lesion, higher quantity and quality of adaptive immune cells, including B- and T-cells. Thus, the inventors propose that early carcinogenesis is shaped by noncoding RNA expression and immune microenvironment. These compelling findings reveal potential early biomarkers and targets for prophylactic immune modulation approaches in individuals at high risk of developing colorectal cancer.

This invention provides an optimized method for enhancing self-amplifying RNA expression and an enhanced self-amplifying RNA. Specifically, it provides an optimized method for enhancing self-amplifying RNA expression, which involves codon optimization. The optimized region is a specific region of the alphavirus non-structural protein sequence of the self-amplifying RNA, where the alphavirus non-structural protein is nsP1234. It also provides a method for preparing the enhanced self-amplifying RNA, an enhanced self-amplifying RNA, and a plasmid. This application improves the expression efficiency of the self-amplifying RNA target gene by designing and constructing codon sequence optimization for certain regions of these non-structural proteins.

The invention relates to the technical field of biological information, in particular to a system and a method for predicting drug sensitivity of generic cancer brain metastatic tumor and a medium. According to the drug sensitivity prediction system for the generic cancer brain metastasis tumor, the sensitivity of a brain metastasis sample to a drug is predicted by constructing a key regulatory factor set of the brain metastasis tumor sample. The drug sensitivity prediction system for the pan-cancer brain metastatic tumor can carry out drug sensitivity prediction and screening on a brain metastatic tumor sample in a targeted mode, operability is high, prediction can be completed only through an RNA expression profile, and butt joint with a clinical conventional sequencing process is facilitated; the output of the prediction result of the prediction system is based on the key regulation factor set, the interpretability is high, the accuracy is high, and low-cost, rapid and interpretable screening of drugs can be realized. The drug sensitivity prediction system for the generic cancer brain metastasis tumor provides key technical support for clinical drug screening of the generic cancer brain metastasis tumor.

The invention discloses a near-infrared RNA fluorescent probe, a preparation method of the near-infrared RNA fluorescent probe and application of the near-infrared RNA fluorescent probe in super-resolution imaging dynamic analysis of nucleolus RNA, and belongs to the technical field of fluorescent probes. The probe is a quinoline-benzothiazole salt derivative, and has the advantages of near-infrared emission, large Stokes shift, high RNA binding affinity and excellent light stability. The molecular marker can quickly penetrate through a cell membrane, specifically marks nucleolus RNA and is hardly interfered by DNA (Deoxyribose Nucleic Acid). And in combination with a structured light illumination microscope, ultra-clear imaging with the resolution of about 100 nm can be realized, and substructures such as a fiber center and a compact fiber component in a nucleolus can be accurately analyzed. Compared with SYTO RNA Select, the probe has the advantages that the combination is stronger, the light stability is better, the probe is successfully applied to real-time monitoring of dynamic changes of nucleolus RNA in the ferroptosis process, the evolution rule of nucleolus morphology and RNA expression in a fatty liver disease model is disclosed, and an efficient tool is provided for research of related mechanisms of nucleolus.

The present application relates to compositions and methods for analyzing simultaneously DNA damage with gene expression from the same cells.

The invention belongs to the technical field of bioinformatics and computational biology, and particularly relates to a dynamic quantile standardization method and system for cross-platform heterogeneous data and application of the dynamic quantile standardization method and system. Through a gene expression scoring algorithm, the method can effectively integrate RNA expression data of different platforms, batches and formats. Gene expression values are sorted and scored, and batch effects and background differences among different data sets are eliminated, so that more accurate and reliable integrated data are generated. The method is simple, convenient and high in adaptability, can process multiple types of gene expression data, does not need to depend on complex model hypothesis or deep learning technology, and remarkably improves the accuracy, reliability and universality of data analysis.

The invention discloses a DNA molecular diagnosis system based on RNA expression level. The diagnosis system comprises an input module, a classification module and an output module, the input module is used for converting collected RNA in serum into DNA molecules and inputting the DNA molecules into the diagnosis system; the classification module comprises a DNA molecular calculation network, and the DNA molecular calculation network implements a silicon-based diagnosis model on a molecular level; and the output module is used for outputting the classification result calculated by the classification module. The invention further discloses a construction method of the DNA molecular diagnosis system and application of the DNA molecular diagnosis system or the construction method, and the DNA molecular diagnosis system or the construction method has wide application value.

PROBLEM TO BE SOLVED: The purpose of the present invention is to provide a novel target gene translation guidance system. SOLUTION: Provided as a translation control system for a target gene in an animal cell is a system that contains a nucleic acid including a translation control region located upstream of the target gene and a predetermined RNA expression vector or a virus that expresses the predetermined RNA in the animal cell. The translation control region has a sequence complementary to the predetermined RNA in the sense strand of the target gene and contains a nucleic acid that forms at least one stem structure.